Miovision Sets New Standard in V2X Innovation with Global Expansion and Smart Mobility Solutions
Breakthroughs like the White Alert System are driving real-world impact, advancing the way vehicles, infrastructure, and people interact on city streets.
'We're not just building solutions for today's transportation challenges—we're defining a future where safety, sustainability, and seamless mobility intersect,' said Kurtis McBride, CEO of Miovision. 'By integrating V2X technology with our promise of innovation, our team is empowering cities every day to create environments where people and vehicles coexist harmoniously.'
Unparalleled Innovation in V2X Technology
Miovision's White Alert System recently earned top honors in the U.S. Department of Transportation's Intersection Safety Challenge for its real-time detection of potential collisions. Designed to protect vulnerable road users (VRUs), the system helps prevent crashes before they happen, supporting Miovision's broader mission to eliminate traffic-related fatalities. By applying smart, responsive technology to city intersections, Miovision is helping make urban mobility safer and more efficient.
Key offerings, such as the Personal Signal Assistant, provide drivers with real-time traffic signal updates, optimizing speed and reducing stop-and-go driving. These innovations have proven their potential to deliver measurable results, including reducing congestion by 15% and cutting collision risks by 20%.
Global Reach, Local Impact
Miovision's V2X solutions serve as the backbone of smart city initiatives, empowering urban planners, transportation engineers, and policymakers with tools that integrate seamlessly with existing infrastructure.
From North America to Europe, cities are turning to Miovision to enhance traffic flow, improve safety, and advance their sustainability initiatives. The company's adaptable platform aligns with public policy objectives while supporting the growing demand for connected and autonomous vehicle infrastructure.
'Whether it's empowering a city in Austin, Texas, to achieve data-driven mobility solutions, or driving smarter, sustainable traffic strategies in Munich, Germany, Miovision is the global partner cities rely on,' added McBride.
Defining the Future of Mobility
With the global V2X market projected to grow from $800 million in 2020 to $15 billion by 2027, Miovision is helping cities of all sizes tap into this momentum. By deploying scalable and cost-effective technologies, the company ensures accessibility for cities with varying budgets and infrastructure capabilities.
With this impressive growth trajectory, the V2X (Vehicle-to-Everything) market is poised to revolutionize the interaction between vehicles, infrastructure, and pedestrians, paving the way for smarter, safer, and more efficient transportation systems. Miovision is driving this evolution by developing innovative solutions that not only enhance traffic management but also enable data-driven decision-making for cities.
By combining advanced AI, connectivity, and real-time analytics, it empowers municipalities to optimize traffic flow, reduce congestion, and improve overall road safety, making the promise of smart cities a tangible reality for communities worldwide.
Miovision's focus on precision, adaptability, and transparent data continues to shape the future of urban mobility, making the smart city vision real for communities worldwide. With its bold innovations and global reach, they continue to raise the bar for what's possible in V2X technology.
For more information about Miovision and its groundbreaking V2X solutions, visit miovision.com/v2x.
About Miovision
Miovision is a global leader in intelligent traffic management solutions, empowering cities to enhance road safety, reduce congestion, and foster sustainable urban environments. Since its founding in 2005, Miovision has been at the forefront of innovation, delivering data-driven insights and scalable solutions to transform today's mobility challenges into tomorrow's seamless journeys. With its cutting-edge V2X technology deployed across 70,000 signalized intersections worldwide, Miovision continues to redefine urban transportation.
Media Contact
Company Name: Miovision
Contact Person: Dina Guttensohn
Email: Send Email
Country: Canada
Website: https://miovision.com/
Source: Brand Push
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
NIQ Announces Refinancing Transaction
CHICAGO, August 13, 2025--(BUSINESS WIRE)--NIQ Global Intelligence plc (NYSE: NIQ) (the "Company", or "NIQ"), a leading global consumer intelligence company, today announced the successful refinancing of its Dollar Term Loan facility ("USD TL") and its Euro Term Loan facility ("Euro TL", and together with USD TL, "Term Loan Facilities") and the successful repricing of its revolving credit facility ("RCF"). The transaction, which closed on August 12, 2025, took advantage of a favorable market window to, among other things, extend the maturities and reduce the interest rate spread on the Term Loan Facilities and reduce the interest rate spread on the RCF. The transaction: Repriced and extended $2,264 million USD TL Extended maturity by approximately 2.5 years from March 2028 to October 2030 Reduced spread by 0.75% from SOFR+3.25% to SOFR+2.50% Included a 0.25% spread stepdown upon achieving 3.25x or lower first lien net leverage ratio based on Credit Agreement Adjusted EBITDA Repriced and extended €1,135 million EUR TL Utilized a portion of IPO proceeds to pay down €255 million of the existing EUR TL from €1,390 million to €1,135 million Extended maturity by approximately 2.5 years from March 2028 to October 2030 Reduced spread by 0.25% from EURIBOR+3.25% to EURIBOR+3.00% Included a 0.25% spread stepdown upon achieving 3.25x or lower first lien net leverage based on Credit Agreement Adjusted EBITDA Repriced $750 million RCF Reduced spread by 0.50% from SOFR+2.75% to SOFR+2.25% Included two 0.25% spread stepdowns upon achieving 3.25x and 2.75x or lower, respectively, first lien net leverage based on Credit Agreement Adjusted EBITDA Additionally, NIQ paid down in full the Canadian Term Loan Facility in the amount of CAD$123 million and paid down €255 million of the prior EUR TL from €1,390 million to €1,135 million, using a portion of IPO proceeds Prior to the transaction, NIQ utilized a portion of IPO proceeds to fully repay all outstanding principal amounts of its revolving credit facility on July 24, 2025 in the amount of $563 million. "Following the recently completed initial public offering, NIQ proactively chose to optimize the capital structure by extending maturity on the Term Loan Facilities by approximately 2.5 years to October 2030. Through our IPO and successful refinancing, we have reduced interest expense by nearly $100 million per year. We also have built-in interest spread step-downs in our Credit Agreement that could deliver another roughly $10 million of annual interest savings as our net leverage ratio decreases," said Mike Burwell, Chief Financial Officer of NIQ. "Our continued improvement in credit profile is acknowledged by the rating agencies with Moody's and Fitch providing us with a one notch upgrade to B1 and BB-, respectively, and S&P revising our outlook to positive from stable." Additional details on the terms of the amendment will be made available in the Form 10-Q to be filed with the Securities and Exchange Commission on August 14, 2025. About NIQ NIQ is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world's population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™. For more information, please visit Forward-looking Statements This press release contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including the expected benefits of the refinancing transaction and other statements contained in this press release that are not historical facts. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, risks and uncertainties related to market conditions and the risks identified under the heading "Risk Factors" in our final prospectus dated July 22, 2025, and filed with the Securities and Exchange Commission on July 24, 2025, as well as the other information we file with the SEC. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. NIQ-IR View source version on Contacts Investors: Media: Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
This AI Chip Stock Is Betting on Its Next Phase of Innovation. Should You Buy It Here?
Astera Labs (ALAB) is earning investor attention following a blowout second quarter that exceeded consensus estimates across revenue, margins, and earnings. The stock has rocketed up almost 42% over the last week, driven by enthusiasm over its potential to be a player in the upcoming second generation of artificial intelligence infrastructure, a market inflection point that its management sees adding a whopping $5 billion to its addressable market by 2030. Deeper partnerships with leading players such as Nvidia (NVDA), Advanced Micro Devices (AMD), and Alchip Technologies are setting up the company at the forefront of next-generation data center networking. More News from Barchart This High-Yield (7%) Dividend Stock Is Down Significantly in 2025. Should You Buy the Dip? Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! About Astera Labs Stock Astera Labs (ALAB) designs high-performance semiconductor connectivity solutions, including PCIe, CXL, and Ethernet-based products for hyperscale data centers. Headquartered in San Jose, California, the company has a market capitalization of approximately $29.8 billion and serves a global customer base that includes leading GPU, CPU, and custom ASIC manufacturers. Shares have soared from a 52-week low of $36.85 to a high of $193.77, returning a gain of nearly 400% compared to a 20% gain for the S&P 500 Index ($SPX) during the comparable period. Thus far this year, ALAB has beaten most peers in the semiconductor group, led by impressive financial performance and healthy demand for its Intelligent Connectivity Platform. Valuation is stretched, with ALAB trading at a forward price-earnings ratio of 364.81x and a price-sales ratio of 75.2x, significantly above semiconductor industry norms. These levels reflect high investor expectations but also heighten sensitivity to any execution risks. The company does not pay a dividend, instead reinvesting in R&D and market expansion. Astera Labs Beats on EPS In Q2 2025, Astera Labs reported revenue of $191.9 million, up 20% sequentially and 150% year-over-year, exceeding prior guidance. The non-GAAP gross margin expanded to 76%, while its operating margin reached 39.2%, resulting in EPS of $0.44. Operating cash flow climbed to $135.4 million, with $1.07 billion in cash, cash equivalents, and marketable securities at quarter's end. Management is guiding for Q3 revenue between $203 million and $210 million, up 6%-9% quarter over quarter, and non-GAAP EPS of $0.38–$0.39. The growth is anticipated across its Aries, Taurus, and Scorpio product lines, and the Scorpio X-Series launch is scheduled for the latter part of 2025 CEO Jitendra Mohan emphasized Astera's positioning in AI Infrastructure 2.0, highlighting expanded work with Nvidia on NVLink Fusion, AMD on UALink, and Alchip Technologies on integrated ASIC and connectivity solutions. These initiatives aim to capture growing demand for rack-scale AI connectivity in the hyperscale market. What Do Analysts Expect for Astera Labs Stock? ALAB earns a 'Strong Buy' rating consensus rating based on 10 'Strong Buy' ratings, one 'Moderate Buy,' and three 'Hold.' The mean price target is $160.62 represents potential downside of 17% from current levels. The highest target of $215 implies upside of about 12%. On the date of publication, Yiannis Zourmpanos had a position in: NVDA, AMD. All information and data in this article is solely for informational purposes. This article was originally published on Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
15 minutes ago
- Yahoo
SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results
IRVINE, Calif., August 13, 2025--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (NASDAQ: SBC, "SBC Medical" or the "Company"), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025). Second Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $15 million, representing a 47% year-over-year decrease. Net Income attributable to SBC Medical Group was $2.5 million, representing an 87% year-over-year decrease. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.02 for the three months ended June 30, 2025, compared to $0.20 in the same period of 2024. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $15 million, representing a 46% year-over-year decrease. EBITDA margin1 was 35% for the second quarter of 2025, compared to 53% for second quarter of 2024. Return on equity, which is defined as net income attributable to the Company divided by the average of shareholder's equity as of June 30, 2025, was 4% representing a year-over-year decrease of 44 percentage points. Number of Franchise Locations2 was 259 as of June 30, 2025, representing an increase of 36 locations from June 30, 2024. Number of customers3 in the last twelve months ended June 30, 2025, was 6.31 million, representing a 14% year-over-year increase. Repeat rate for customers4 who visited franchisee's clinics twice or more was 72%. Total revenues were $91 million, representing a 16% year-over-year decrease. Income from operations was $39 million, representing a 25% year-over-year decrease. Net Income attributable to SBC Medical Group was $24 million, representing a 36% year-over-year decrease. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.23 for the six months ended June 30, 2025, compared to $0.40 in the same period of 2024. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $40 million, representing a 25% year-over-year decrease. EBITDA margin1 was 44% for the first half of 2025, compared to 50% for first half of 2024. Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, " As anticipated and signaled in our prior guidance, Q2 2025 reflected strategic shifts aimed to position SBC Medical for long-term competitiveness and scalability. Total revenue declined 18% year-over-year to $43 million, primarily due to the completed discontinuation of our staffing business, targeted divestitures to streamline our operations, and revision of fee structure. We are executing our strategic plan with precision, as evidenced by our network of 259 Franchise Locations as of June 30, 2025 and 6.31 million visits over the last twelve months, demonstrating a scale that is unmatched in Japan. Our high repeat rate underscores the strength of our Shonan Beauty Clinic brand. Japan's consumer discretionary market faces challenges, including restrained growth due to trade restrictions and cautious consumer spending. Despite these headwinds, we are successfully advancing key initiatives, including the acquisition of MB career lounge to enhance our management support services and the joining of JUN CLINIC to our network, which boasts a high average spend per customer. Looking ahead, we remain confident in our strategic roadmap, focused on optimizing our franchise model, capturing growth opportunities, transitioning to higher-margin models, and delivering lasting value to our shareholders." Second Quarter 2025 Financial Results Total revenues were $43 million, a decrease of 18% year-over-year, primarily due to a revised fee structure for franchising services implemented starting from April 2025, the discontinuation staffing services business, and divestiture of SNA and Kijimadaira, partially offset by growth in procurement, rental services, and other revenue streams. Net income attributable to SBC Medical Group for the three months ended June 30, 2025 was $2.5 million, compared to $18.5 million in the same period of 2024. The decrease was largely attributed to unfavorable changes in other income and expenses, primarily due to higher foreign exchange losses. EBITDA1 was $15 million, a decrease of 46% year-over-year, primarily due to lower revenue following the termination of the staffing services business, the deconsolidation of SNA and Kijimadaira, and revision of fee structure. Conference Call The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided It will automatically direct you to the registration page of "SBC Q2 2025 Financial Results Presentation.". Please follow the steps to enter your registration details, then click "Submit.". Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past investor relations materials. Starting 10 minutes before the conference call begins, you will be able to view the earnings presentation materials on the site. The materials will also be available for download. A replay of the conference call will be accessible until August 13, 2026. Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company's Investor Relations website at About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals, construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise clinic's customer rewards program (customer loyalty point program), and payment tools for the franchise clinics. For more information, visit Use of Non-GAAP Financial Measures The Company uses non-GAAP measures, such as EBITDA and EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes that the non-GAAP financial measures provide useful information about the Company's results of operations, enhance the overall understanding of the Company's past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company's operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance. For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP Results." Forward Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at 1 EBITDA and EBITDA Margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section "Use of Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP Results." 2 The figures take into accounts of the franchising of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH, JUN CLINIC 3 The number of customers takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, AHH Clinic but does not take account of customers of JUN CLINIC, but excluding free counseling. The applicable periods are from July 1, 2024, to June 30, 2025 4 The figures include franchising of SBC brand clinics, Rize Clinic, and Gorilla Clinic, but does not take account of customers of AHH clinics and JUN CLINIC excluding free counseling. The percentage of customers who visited our franchisee's clinics twice or more. SBC MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 152,740,882 $ 125,044,092 Accounts receivable 2,350,368 1,413,433 Accounts receivable – related parties 48,920,843 28,846,680 Inventories 1,705,237 1,494,891 Finance lease receivables, current – related parties 9,128,931 5,992,585 Customer loans receivable, current 10,552,623 10,382,537 Prepaid expenses and other current assets 14,051,746 11,276,802 Other receivables – related parties 1,891,408 — Total current assets 241,342,038 184,451,020 Non-current assets: Property and equipment, net 8,058,016 8,771,902 Intangible assets, net 1,584,543 1,590,052 Long-term investments, net 3,593,087 3,049,972 Goodwill, net 5,011,511 4,613,784 Cryptocurrencies 535,882 — Finance lease receivables, non-current – related parties 13,197,979 8,397,582 Operating lease right-of-use assets 4,583,393 5,267,056 Finance lease right-of-use assets 516,932 — Deferred tax assets 2,343,302 9,798,071 Customer loans receivable, non-current 5,934,636 5,023,551 Long-term prepayments 1,755,292 1,745,801 Long-term investments in MCs – related parties 19,381,422 17,820,910 Other assets 7,461,224 15,553,453 Total non-current assets 73,957,219 81,632,134 Total assets $ 315,299,257 $ 266,083,154 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 16,290,206 $ 13,875,179 Accounts payable – related parties 3,245,989 659,044 Current portion of long-term loans 69,420 96,824 Notes and other payables, current – related parties 3,272,048 26,255 Advances from customers 512,123 820,898 Advances from customers – related parties 10,333,007 11,739,533 Income tax payable 14,133,163 18,705,851 Operating lease liabilities, current 3,623,871 4,341,522 Finance lease liabilities, current 161,340 — Accrued liabilities and other current liabilities 6,229,797 8,103,194 Due to related party 2,810,647 2,823,590 Total current liabilities 60,681,611 61,191,890 SBC MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED BALANCE SHEETS — (Continued) June 30, 2025 December 31, 2024 Non-current liabilities: Long-term loans 7,031,506 6,502,682 Notes and other payables, non-current – related parties — 5,334 Deferred tax liabilities 353,517 926,023 Operating lease liabilities, non-current 1,208,516 1,241,526 Finance lease liabilities, non-current 164,721 — Other liabilities 1,206,815 1,193,541 Total non-current liabilities 9,965,075 9,869,106 Total liabilities 70,646,686 71,060,996 Stockholders' equity: Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024) — — Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 and 103,020,816 shares issued, 103,098,442 and 102,750,816 shares outstanding as of June 30, 2025 and December 31, 2024, respectively) 10,388 10,302 Additional paid-in capital 72,196,114 62,513,923 Treasury stock (at cost, 782,809 and 270,000 shares as of June 30, 2025 and December 31, 2024, respectively) (5,115,262 ) (2,700,000 ) Retained earnings 213,423,693 189,463,007 Accumulated other comprehensive loss (35,922,942 ) (54,178,075 ) Total SBC Medical Group Holdings Incorporated stockholders' equity 244,591,991 195,109,157 Non-controlling interests 60,580 (86,999 ) Total stockholders' equity 244,652,571 195,022,158 Total liabilities and stockholders' equity $ 315,299,257 $ 266,083,154 The accompanying notes are an integral part of these unaudited consolidated financial MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS ANDCOMPREHENSIVE INCOME For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 Revenues, net – related parties $ 38,944,898 $ 51,039,038 $ 84,202,043 $ 101,509,245 Revenues, net 4,413,949 2,063,042 6,485,505 6,400,877 Total revenues, net 43,358,847 53,102,080 90,687,548 107,910,122 Cost of revenues (including cost of revenues from related parties of $4,669,602 and $3,616,103 for the three months ended June 30, 2025 and 2024, and $8,126,530 and $5,413,462 for the six months ended June 30, 2025 and 2024, respectively) 13,348,270 13,682,405 22,943,887 28,971,072 Gross profit 30,010,577 39,419,675 67,743,661 78,939,050 Operating expenses: Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $415,767 and nil for the three months ended June 30, 2025 and 2024, and $415,767 and nil for the six months ended June 30, 2025 and 2024, respectively) 15,456,385 12,129,115 28,987,395 27,187,605 Total operating expenses 15,456,385 12,129,115 28,987,395 27,187,605 Income from operations 14,554,192 27,290,560 38,756,266 51,751,445 Other income (expenses): Interest income 22,882 11,644 78,215 29,333 Interest expense (49,651 ) (7,424 ) (55,858 ) (10,432 ) Other income 33,771 306,291 185,099 655,972 Other expenses (1,132,465 ) (514,636 ) (2,829,724 ) (1,951,292 ) Gain on redemption of life insurance policies — — 8,746,138 — Change in fair value of cryptocurrencies 111,632 — 111,632 — Gain on disposal of subsidiary — — — 3,813,609 Total other income (expenses) (1,013,831 ) (204,125 ) 6,235,502 2,537,190 Income before income taxes 13,540,361 27,086,435 44,991,768 54,288,635 Income tax expense 11,100,509 8,529,110 21,059,966 16,981,094 Net income 2,439,852 18,557,325 23,931,802 37,307,541 Less: net income (loss) attributable to non-controlling interests (18,388 ) 72,917 (28,884 ) 65,381 Net income attributable to SBC Medical Group Holdings Incorporated $ 2,458,240 $ 18,484,408 $ 23,960,686 $ 37,242,160 Other comprehensive income (loss): Foreign currency translation adjustment $ 8,623,269 $ (9,046,549 ) $ 18,431,596 $ (19,240,401 ) Total comprehensive income 11,063,121 9,510,776 42,363,398 18,067,140 Less: comprehensive income (loss) attributable to non-controlling interests 184,411 22,000 147,579 (70,000 ) Comprehensive income attributable to SBC Medical Group Holdings Incorporated $ 10,878,710 $ 9,488,776 $ 42,215,819 $ 18,137,140 Net income per share attributable to SBC Medical Group Holdings Incorporated* Basic and diluted $ 0.02 $ 0.20 $ 0.23 $ 0.40 Weighted average shares outstanding* Basic and diluted 103,507,249 94,192,433 103,392,580 94,192,433 * Retrospectively restated for effect of reverse recapitalization on September 17, 2024. The accompanying notes are an integral part of these unaudited consolidated financial MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net income $ 23,931,802 $ 37,307,541 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization expense 1,264,405 1,849,422 Non-cash lease expense 2,185,744 1,923,890 Provision for credit losses 283,752 62,804 Fair value change of long-term investments 384,523 1,045,557 Gain on disposal of subsidiary — (3,813,609 ) Gain on redemption of life insurance policies (8,746,138 ) — Gain on disposal of property and equipment (10,804 ) (902 ) Change in fair value of cryptocurrencies (111,632 ) — Deferred income taxes 7,452,983 (3,322,728 ) Changes in operating assets and liabilities: Accounts receivable (789,577 ) (1,423,412 ) Accounts receivable – related parties (17,039,113 ) 5,843,499 Inventories (717,972 ) 561,921 Finance lease receivables – related parties (6,482,967 ) (1,759,556 ) Customer loans receivable 8,081,703 7,521,267 Prepaid expenses and other current assets (1,349,225 ) (1,488,347 ) Long-term prepayments 211,988 (41,412 ) Other assets 85,907 (1,007,431 ) Accounts payable 1,165,217 (8,960,556 ) Accounts payable – related parties 2,455,865 — Notes and other payables – related parties (5,031,570 ) (5,101,368 ) Advances from customers (369,616 ) (755,977 ) Advances from customers – related parties (2,363,891 ) (4,663,233 ) Income tax payable (6,030,526 ) 5,462,133 Operating lease liabilities (2,275,398 ) (1,998,196 ) Accrued liabilities and other current liabilities (2,508,035 ) (4,444,172 ) Other liabilities (88,593 ) 77,625 NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES (6,411,168 ) 22,874,760 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (560,431 ) (1,565,333 ) Purchase of convertible note — (1,700,000 ) Prepayments for property and equipment (705,351 ) — Advances to related parties — (617,804 ) Payments made on behalf of related parties (1,836,541 ) (5,245,990 ) Purchase of long-term investments (652,555 ) — Purchase of cryptocurrencies (424,250 ) — Long-term loans to others (13,134 ) (62,489 ) Repayments from related parties 70,000 555,000 Repayments from others 56,307 44,748 Proceeds from redemption of life insurance policies 17,735,717 — Disposal of subsidiary, net of cash disposed of — (815,819 ) Proceeds from disposal of property and equipment 1,728,236 1,971 NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 15,397,998 (9,405,716 ) SBC MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued) For the Six Months EndedJune 30, 2025 2024 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings from related parties 15,000 — Repayments of long-term loans (74,256 ) (59,217 ) Repayments of finance lease liabilities (278,097 ) — Repayments to related parties (27,943 ) (50,124 ) Repurchase of common stock (2,415,262 ) — Deemed contribution in connection with price modification on disposal of property and equipment 9,682,277 — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 6,901,719 (109,341 ) Effect of exchange rate changes 11,808,241 (12,679,865 ) NET CHANGE IN CASH AND CASH EQUIVALENTS 27,696,790 679,838 CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD 125,044,092 103,022,932 CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD $ 152,740,882 $ 103,702,770 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for interest expense $ 55,858 $ 10,432 Cash paid for income taxes, net $ 19,637,454 $ 16,191,178 NON-CASH INVESTING AND FINANCING ACTIVITIES Property and equipment transferred from long-term prepayments $ 246,188 $ — Operating lease right-of-use assets obtained in exchange for operating lease liabilities $ 104,437 $ — Finance lease right-of-use assets obtained in exchange for finance lease liabilities $ 612,466 $ — Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications $ 1,160,680 $ 1,376,034 Payables to related parties in connection with loan services provided $ 8,175,342 $ 16,085,387 Issuance of common stock as incentive shares $ 86 $ — The accompanying notes are an integral part of these unaudited consolidated financial OF GAAP TO NON-GAAP FINANCIAL MEASURES SBC MEDICAL GROUP HOLDINGS INCORPORATEDUnaudited Reconciliations of GAAP and Non-GAAP Results For the Three Months EndedJune 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Total revenues, net $ 43,358,847 $ 53,102,080 $ 90,687,548 107,910,122 Income from operations 14,554,192 27,290,560 38,756,266 51,751,445 Depreciation and amortization expense 636,101 830,945 1,264,405 1,849,422 EBITDA 15,190,293 28,121,505 40,020,671 53,600,867 EBITDA margin 35 % 53 % 44 % 50 % The accompanying notes are an integral part of these unaudited consolidated financial statements. View source version on Contacts In Asia:SBC Medical Group Holdings IncorporatedHikaru Fukui / Head of Investor RelationsE-mail: ir@ In the US:ICR LLCBill Zima / Managing PartnerEmail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
